We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Escitalopram in Schizophrenia in OCD- Open Label Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00456937
First Posted: April 5, 2007
Last Update Posted: January 27, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Lundbeck Israel
Information provided by:
BeerYaakov Mental Health Center
  Purpose
SSRI's has been demonstrated to be partially effective in schizophrenia and OCD. We therefore suggest that Escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology

Condition Intervention Phase
Schizophrenia Drug: Escitalopram Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Escitalopram in the Treatment of Patient Suffering From Scizophrenia and Obsessive Compulsive Disorder- an Open Label Study

Resource links provided by NLM:


Further study details as provided by BeerYaakov Mental Health Center:

Estimated Enrollment: 15
Study Start Date: July 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who suffer from schizophrenia and OCD

Exclusion Criteria:

  • Substance abuse,
  • Serious medical condintions,
  • Being on SSRI treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00456937


Locations
Israel
Beer Yaakov MHC
Beer Yaakov, Israel, 70350
Sponsors and Collaborators
BeerYaakov Mental Health Center
Lundbeck Israel
Investigators
Principal Investigator: Rafael Octavio Stryjer, M.D. Beer Yaakov Mental Health Center
  More Information

Responsible Party: Dr Rafael Stryjer, Beer-Yaakov MHC
ClinicalTrials.gov Identifier: NCT00456937     History of Changes
Other Study ID Numbers: Escitalopram-173CTIL
First Submitted: December 3, 2006
First Posted: April 5, 2007
Last Update Posted: January 27, 2009
Last Verified: January 2009

Additional relevant MeSH terms:
Schizophrenia
Obsessive-Compulsive Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Anxiety Disorders
Citalopram
Dexetimide
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents